- Mayne Pharma Limited
SummaryHospira Inc and Mayne Pharma Limited operate in the pharmaceutical industry in Australia.
Market definitionThe ACCC considered Hospira Inc's proposed acquisition of Mayne Pharma Limited in the context of a national market for the manufacture and supply of dobutamine injectables.
Competition analysisThe ACCC considered that Hospira Inc would face sufficient competitive constraints post-acquisition and that the proposed acquisition is unlikely to cause a substantial lessening of competition in the relevant market. This conclusion was informed by the following factors:
- substitutes are available to hospitals and pharmaceutical wholesalers for the supply of dobutamine injectables;
- customers for dobutamine injectables have some countervailing power; and
- barriers to entry are moderate into the manufacture and supply of dobutamine injectables for existing pharmaceutical companies.
|20/10/2006||ACCC commenced review under the Merger Review Process Guidelines. Market inquiries commenced|
|09/11/2006||Closing date for submissions from interested parties|
|15/11/2006||ACCC announced its decision not to oppose the proposed acquisition|